Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

[1]  H. Joensuu,et al.  A Phase I Study of Raltitrexed (Tomudex) Combined with Carmofur in Metastatic Colorectal Cancer , 2001, Oncology.

[2]  S. Clarke,et al.  Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  S. Steinberg,et al.  A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  W. Berry,et al.  ‘Tomudex’ (raltitrexed) 4.0 mg/m[2] as second- or third-line therapy in patients with advanced colorectal cancer: a Phase II study , 1999 .

[5]  R. Labianca,et al.  Which 5-fluorouracil regimen?--the great debate. , 1999, Anti-cancer drugs.

[6]  S. Kudoh,et al.  [Phase I study of raltitrexed (ZD-1694)]. , 1998, Gan to kagaku ryoho. Cancer & chemotherapy.

[7]  D. Kerr,et al.  Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. , 1998, European journal of cancer.

[8]  P. Beale,et al.  Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694). , 1998, British Journal of Cancer.

[9]  D. Kerr,et al.  Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Zalcberg.  Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer , 1997, Anti-cancer drugs.

[11]  D. Kerr,et al.  Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  S. Clarke,et al.  Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  I. Seymour,et al.  ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Jackman,et al.  ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. , 1995, European journal of cancer.

[15]  Robert B. Diasio,et al.  Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.

[16]  D. Kerr,et al.  Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06 , 2000 .

[17]  P. Beale,et al.  Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients , 1998, Cancer Chemotherapy and Pharmacology.

[18]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .